array:24 [ "pii" => "S2529993X18300054" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2017.10.010" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "1760" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:586-92" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 268 "formatos" => array:2 [ "HTML" => 175 "PDF" => 93 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0213005X17303026" "issn" => "0213005X" "doi" => "10.1016/j.eimc.2017.10.008" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "1760" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:586-92" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 3666 "formatos" => array:3 [ "EPUB" => 2 "HTML" => 2034 "PDF" => 1630 ] ] "es" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Formación médica continuada: Infecciones por micobacterias</span>" "titulo" => "Tratamiento de las infecciones producidas por micobacterias no tuberculosas" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "586" "paginaFinal" => "592" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Treatment of infections caused by nontuberculous mycobacteria" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 631 "Ancho" => 1000 "Tamanyo" => 96658 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Enfermedad cavitaria por <span class="elsevierStyleItalic">Mycobacterium avium</span> (TAC).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jaime Esteban, Enrique Navas" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jaime" "apellidos" => "Esteban" ] 1 => array:2 [ "nombre" => "Enrique" "apellidos" => "Navas" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2529993X18300054" "doi" => "10.1016/j.eimce.2017.10.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X18300054?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17303026?idApp=UINPBA00004N" "url" => "/0213005X/0000003600000009/v1_201810300628/S0213005X17303026/v1_201810300628/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2529993X1830162X" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2018.07.002" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "1745" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:593-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 367 "formatos" => array:2 [ "HTML" => 295 "PDF" => 72 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Diagnosis at first sight</span>" "titulo" => "Splenic infarction due a common infection" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "593" "paginaFinal" => "595" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Infarto esplénico debido a una infección común" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Fig. 5" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr5.jpeg" "Alto" => 1064 "Ancho" => 1667 "Tamanyo" => 115616 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Follow-up ultrasound showing exclusively a small hypodense lesion measuring around 12–13<span class="elsevierStyleHsp" style=""></span>mm on the inferior splenic pole.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Javier García-Vázquez, Raquel Plácido Paias, Manuel Portillo Márquez" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Javier" "apellidos" => "García-Vázquez" ] 1 => array:2 [ "nombre" => "Raquel" "apellidos" => "Plácido Paias" ] 2 => array:2 [ "nombre" => "Manuel" "apellidos" => "Portillo Márquez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213005X17302409" "doi" => "10.1016/j.eimc.2017.09.007" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17302409?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X1830162X?idApp=UINPBA00004N" "url" => "/2529993X/0000003600000009/v1_201810300607/S2529993X1830162X/v1_201810300607/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2529993X18302211" "issn" => "2529993X" "doi" => "10.1016/j.eimce.2017.06.011" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "1712" "copyright" => "Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Enferm Infecc Microbiol Clin. 2018;36:576-85" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 255 "formatos" => array:2 [ "HTML" => 181 "PDF" => 74 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Consensus statement</span>" "titulo" => "Consensus document on the diagnosis and treatment of sexually transmitted diseases in adults, children and adolescents" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "576" "paginaFinal" => "585" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Documento de consenso sobre diagnóstico y tratamiento de las infecciones de transmisión sexual en adultos, niños y adolescentes" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => " National AIDS Plan" "autores" => array:5 [ 0 => array:1 [ "colaborador" => "AIDS Study Group (GESIDA)" ] 1 => array:1 [ "apellidos" => "National AIDS Plan" ] 2 => array:1 [ "colaborador" => "STI Study group of the SEIMC (GEITS)" ] 3 => array:1 [ "colaborador" => "Spanish Group for the Investigation of Sexual Transmission Diseases of the Spanish Academy of Dermatology and Venerology" ] 4 => array:1 [ "colaborador" => "The Spanish Society for Pediatric Infectious (SEIP)" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0213005X17301908" "doi" => "10.1016/j.eimc.2017.06.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213005X17301908?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X18302211?idApp=UINPBA00004N" "url" => "/2529993X/0000003600000009/v1_201810300607/S2529993X18302211/v1_201810300607/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Continuing medical education: Mycobacterial infections</span>" "titulo" => "Treatment of infections caused by nontuberculous mycobacteria" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "586" "paginaFinal" => "592" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Jaime Esteban, Enrique Navas" "autores" => array:2 [ 0 => array:4 [ "nombre" => "Jaime" "apellidos" => "Esteban" "email" => array:1 [ 0 => "jestebanmoreno@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Enrique" "apellidos" => "Navas" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Departamento de Microbiología Clínica, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento de las infecciones producidas por micobacterias no tuberculosas" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 676 "Ancho" => 1000 "Tamanyo" => 129486 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Nodulary disease due to <span class="elsevierStyleItalic">Mycobacterium avium</span> (CT scan).</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Today, the genus <span class="elsevierStyleItalic">Mycobacterium</span> includes over 150 different species.<a class="elsevierStyleCrossRefs" href="#bib0200"><span class="elsevierStyleSup">1,2</span></a> The group of mycobacteria different from <span class="elsevierStyleItalic">Mycobacterium tuberculosis</span> complex (<span class="elsevierStyleItalic">M. bovis</span>, <span class="elsevierStyleItalic">M. africanum</span>, <span class="elsevierStyleItalic">M. microti</span>, <span class="elsevierStyleItalic">M. canetti</span>, <span class="elsevierStyleItalic">M. caprae</span>, <span class="elsevierStyleItalic">M. pinnipedii</span>, <span class="elsevierStyleItalic">M. suricattae</span> and <span class="elsevierStyleItalic">M. mungi</span>) and the group of mycobacteria causing leprosy (<span class="elsevierStyleItalic">M. leprae</span> and <span class="elsevierStyleItalic">M. lepromatosis</span>) are usually referred to as atypical, environmental, or nontuberculous mycobacteria (NTM); these are microorganisms widely distributed in the environment with a non-uniform distribution and regional variations that are possibly due to not very well known environmental factors.</p><p id="par0010" class="elsevierStylePara elsevierViewall">NTM are traditionally classified based on their phenotypical characteristics into two (2) different groups: slowly growing mycobacteria, and rapidly growing mycobacteria. Today's molecular biology techniques have greater discrimination capabilities are at the base of the taxonomic classification and epidemiological typing of NTM, and the advances made on this area are the reason why, during the last few years, a great deal of species and subspecies of mycobacteria have been added, and reclassified.</p><p id="par0015" class="elsevierStylePara elsevierViewall">Unlike <span class="elsevierStyleItalic">M. tuberculosis</span> and <span class="elsevierStyleItalic">M. leprae</span>, the association of NTM with human pathology is occasional and opportunistic; as a matter of fact, most species have never be categorized as human pathogens, and only a relatively small group of them are common human pathogens, mostly in patients with predisposing factors, since the capacity of these mycobacteria to cause disease depends not only on intrinsic pathogenicity factors of the different species, but also on host factors such as the integrity of the immune system, or the presence of loco-regional factors (surgical incision; prior tissue pathology; foreign body; etc.).<a class="elsevierStyleCrossRef" href="#bib0210"><span class="elsevierStyleSup">3</span></a> The larger number of patients with this type of risk factors such as HIV-co-infection, the higher survival rates of onco-hematological patients and transplant receivers, or with other chronic conditions such as COPD and cystic fibrosis, and the growing use of biomedical devices explain the increased infection rate reported during the last few years.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Within the wide group of possible syndromes called mycobacteriosis we find respiratory infections, commonly associated with prior pulmonary conditions such as cystic fibrosis, COPD, bronchiectasias, etc.; disseminated infections, usually associated with immunodeficiencies; skin and soft tissue infections including lymphadenitis; and surgical bed infections associated, or not, with the implantation of biomaterials.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Disseminated infections are usually related to immunosuppression and they have been reported, above all, in patients with infection due to HIV, onco-hematological patients, transplant receivers, and patients treated with anti-TNF-α; biological drugs; the natural immunity against mycobacteria is based on the interferon-gamma and interleukin 12 pathway—responsible for the control of monocytes, macrophages, and dendritic cells with T-lymphocytes and NK (natural-killers); also, localized and/or disseminated infections due to NTM have been reported both in congenital immunodeficiencies due to mutations in receptors or ligands of this pathway, and in late immunosuppressions due to the development of anti-interferon-gamma bodies.<a class="elsevierStyleCrossRef" href="#bib0215"><span class="elsevierStyleSup">4</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">The microbiological diagnosis of mycobacteriosis is not very different from the diagnosis of tuberculosis from the microbiological standpoint; most NTM grow in culture media common to mycobacteria incubated at 95–98.6<span class="elsevierStyleHsp" style=""></span>°F; however, the culture media of skin and osteo-joint samples use incubation temperatures of 82.4–86<span class="elsevierStyleHsp" style=""></span>°F—optimal temperature for the growth of some species such as <span class="elsevierStyleItalic">M. abscessus</span>, <span class="elsevierStyleItalic">M. ulcerans</span>, or <span class="elsevierStyleItalic">M. marinum</span>. Other species such as <span class="elsevierStyleItalic">M. xenopi</span> grow better at temperatures of 113<span class="elsevierStyleHsp" style=""></span>°F, and others require additional culture media (<span class="elsevierStyleItalic">M. genavense</span> and <span class="elsevierStyleItalic">M. haemophilum</span>), or need prolonged incubation (<span class="elsevierStyleItalic">M. ulcerans</span>, <span class="elsevierStyleItalic">M. genavense</span>, <span class="elsevierStyleItalic">M. malmoense</span>).</p><p id="par0035" class="elsevierStylePara elsevierViewall">Although, for the moment, we do not have rapid direct diagnostic techniques, the sensitivity of the different culture techniques is excellent for most part of the most relevant NTM in the clinical practice and, also, we have rapid and precise identification techniques and one standardized methodology for the study of antimicrobial sensitivity.<a class="elsevierStyleCrossRef" href="#bib0220"><span class="elsevierStyleSup">5</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">However, in the clinical practice, the main problem is establishing the meaning of isolation of these organisms in the clinical samples since the NTM can be pathogens, but also contaminating or colonizing. Identification is very important since species such as <span class="elsevierStyleItalic">M. gordonae</span>, <span class="elsevierStyleItalic">M. terrae</span>, or <span class="elsevierStyleItalic">M. lentiflavum</span> are usually water contaminants and an exceptional cause of pulmonary disease, while species such as <span class="elsevierStyleItalic">M. kansasii</span>, or <span class="elsevierStyleItalic">M. szulgai</span> are pathogens in most cases.</p><p id="par0045" class="elsevierStylePara elsevierViewall">The management of these patients is usually complex and can require not only extended and different antibiotic therapies—based on the mycobacterium that has been isolated, but also the removal of affected devices, or even the use of surgery to eliminate the source of infection in some cases.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Biofilms and therapeutic complications</span><p id="par0050" class="elsevierStylePara elsevierViewall">One especially important aspect in the management of patients with infection due to NTM is the involvement of many of these infections (in particular, pulmonary and material-related infections) in the development of biofilms. These structures are a very important mechanism of antimicrobial resistance in all microorganisms, including mycobacteria. It has been confirmed that different species are capable of developing these structures,<a class="elsevierStyleCrossRefs" href="#bib0225"><span class="elsevierStyleSup">6,7</span></a> and that this development increases antimicrobial resistance with MIC peaks ≥1000 times when the mycobacterium is in sessile form.<a class="elsevierStyleCrossRef" href="#bib0235"><span class="elsevierStyleSup">8</span></a> This increased resistance is probably due to numerous factors such as the penetration capacities of the antibiotic (not very effective), and the bacteria metabolic state that seems to be the essential mechanism, yet others cannot be ruled out, such as the existence of persisters or the activation of resistance genes.<a class="elsevierStyleCrossRef" href="#bib0240"><span class="elsevierStyleSup">9</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">The implications of these facts are very important. In biomaterial-induced infections, the development of biofilms in inert, nonvascularized areas would not allow its eradication through the use of antibiotics only, which means that it is essential to remove the foreign body if we want to cure the patient. In the case of respiratory infections, the involvement of biofilms has recently been reported in clinical cases, meaning that the problems would be similar to the aforementioned case.<a class="elsevierStyleCrossRef" href="#bib0245"><span class="elsevierStyleSup">10</span></a> In these infections, however, there is no foreign body to remove, and all there is to do is adjust the treatment for greater effectiveness against biofilms, and maybe even include in the therapeutic scheme the surgical removal of damaged tissues whenever possible on the technical level.</p><p id="par0060" class="elsevierStylePara elsevierViewall">The search for new strategies in the management of biofilm-induced infections is a developing field and results are still non-applicable to the clinical practice. However, it is possible that in a near future we will have therapeutic patterns specifically designed to treat biofilms that when combined with conventional antibiotic therapies will improve the prognosis of patients.<a class="elsevierStyleCrossRef" href="#bib0250"><span class="elsevierStyleSup">11</span></a></p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Slowly growing mycobacteria</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040"><span class="elsevierStyleItalic">Mycobacterium avium</span> complex</span><p id="par0065" class="elsevierStylePara elsevierViewall">The <span class="elsevierStyleItalic">Mycobacterium avium complex</span> (MAC) is one heterogeneous group of mycobacteria that traditionally includes two (2) different species: <span class="elsevierStyleItalic">M. intracellulare</span>, and <span class="elsevierStyleItalic">M. avium</span> with three (3) subspecies: <span class="elsevierStyleItalic">M. avium</span> subsp. <span class="elsevierStyleItalic">avium</span>, <span class="elsevierStyleItalic">M. avium</span> subsp. <span class="elsevierStyleItalic">Paratuberculosis</span>, and <span class="elsevierStyleItalic">M. avium</span> subsp. <span class="elsevierStyleItalic">silvaticum</span>. Recently, new species have been recognized such as <span class="elsevierStyleItalic">M. chimera</span>—involved in infections acquired after cardiovascular surgery due to water contamination and aerosolization, <span class="elsevierStyleItalic">M. colombiense</span>, <span class="elsevierStyleItalic">M. vulneris</span>, <span class="elsevierStyleItalic">M. marseillense</span>, <span class="elsevierStyleItalic">M. bouchedurhonense</span>, <span class="elsevierStyleItalic">M. yongonense</span>, <span class="elsevierStyleItalic">M. arosiense</span>, <span class="elsevierStyleItalic">M. indicus pranii</span>, and <span class="elsevierStyleItalic">M. timonense</span>.<a class="elsevierStyleCrossRef" href="#bib0255"><span class="elsevierStyleSup">12</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">The MAC is the most common cause of NTM-induced pulmonary infection. Some cases affect patients with chronic obstructive pulmonary disease (COPD, emphysema, asthma, bronchiectasis, prior tuberculosis, etc.), or gastroesophageal reflux, but others may be de novo cases occurring in patients without any preexisting pulmonary conditions or known immunodeficiencies; a part of these cases affects non-smoking slim women, with chronic pulmonary affectation in the form of localized bronchiectasis, which in the medical literature is referred to as the Lady Windermere syndrome. In some of these cases, genetic alterations of mutations in the CFTR gene involved in cystic fibrosis are found to affect the immune system, the ciliary function, or heterozygotes.</p><p id="par0075" class="elsevierStylePara elsevierViewall">MAC-induced and, overall, NTM-induced pulmonary infections have been categorized as fibrocavitary and multibacillary types with a destructive pattern similar to the classic cavitating pulmonary tuberculosis with usually positive staining for acid-alcohol resistant bacilli and nodular bronchiectasic, paucibacillary, and more indolent types that pose differential diagnosis inquiries of slowly progressive pulmonary disease versus the transient airway colonization by NTM (<a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1 and 2</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0080" class="elsevierStylePara elsevierViewall">MAC is also the leading cause of lymphadenitis in kids under 5 years old, ahead of <span class="elsevierStyleItalic">M. scrofulaceum</span> in developed countries,<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">13</span></a> and in HIV-positive patients and in patients with other immunodeficiencies is cause for extrapulmonary and disseminated affectation.</p><p id="par0085" class="elsevierStylePara elsevierViewall">The introduction of macrolides (clarithromycin and azithromycin) has been a huge advancement in the management of MAC-induced infections improving the rates of response compared to the classic course based on rifampicin, isoniazid and ethambutol both for the management of pulmonary infections and HIV infection-related disseminated disease. The combination of one macrolide with ethambutol and one rifamycin (rifampicin or rifabutin) is the basis of the treatment of MAC-induced infections; fluoroquinolones such as amikacin and clofazimine are also active in vitro, although the clinical response and the in vitro resistance only have a good correlation with macrolides in which high MICs to clarithromycin (MIC<span class="elsevierStyleHsp" style=""></span>≥<span class="elsevierStyleHsp" style=""></span>32<span class="elsevierStyleHsp" style=""></span>μg/ml) are clearly associated with therapeutic failure. There is a preliminary experience with the use of inhaled amikacin, especially in advanced cases that are refractory to conventional therapy with somehow clinical and biological benefits. The effectiveness of the use of quinolones (ciprofloxacin, levofloxacin or moxifloxacin) in combination with patterns based on macrolides is dubious and increases the risk of suffering from arrhythmias as a consequence of a prolonged QT interval.</p><p id="par0090" class="elsevierStylePara elsevierViewall">Although there is some controversy on the dose and choice of the macrolide, clarithromycin 1000<span class="elsevierStyleHsp" style=""></span>mg/day (15<span class="elsevierStyleHsp" style=""></span>mg/kg if <50<span class="elsevierStyleHsp" style=""></span>kg), and azithromycin 250<span class="elsevierStyleHsp" style=""></span>mg/day, or 500<span class="elsevierStyleHsp" style=""></span>mg 3 t.i.d. seem equally effective.<a class="elsevierStyleCrossRef" href="#bib0265"><span class="elsevierStyleSup">14</span></a> The same thing happens with rifamycin, being rifampicin 600<span class="elsevierStyleHsp" style=""></span>mg/day, or rifabutin 150–300<span class="elsevierStyleHsp" style=""></span>mg/day probably the same.</p><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Disseminated infection in HIV-positive patients</span><p id="par0095" class="elsevierStylePara elsevierViewall">MAC-induced disseminated infections affect patients with CD4 counts below 50<span class="elsevierStyleHsp" style=""></span>cells/μl; the treatment of choice is the combination of clarithromycin 500<span class="elsevierStyleHsp" style=""></span>mg every 12<span class="elsevierStyleHsp" style=""></span>h, and ethambutol 15<span class="elsevierStyleHsp" style=""></span>mg/kg/day.</p><p id="par0100" class="elsevierStylePara elsevierViewall">Azithromycin has been used as a substitute for clarithromycin for its better digestive tolerance and better profile of pharmacokinetics interactions, and its effectiveness is not inferior to clarithromycin.</p><p id="par0105" class="elsevierStylePara elsevierViewall">The role of rifampicin or rifabutin plus clarithromycin-ethambutol for an early management is not well defined and both pose problems of interaction with antiretroviral drugs. Amikacin is suggested in severe cases and re-treatment courses. In one clinical trial on MAC-induced disseminated infections,<a class="elsevierStyleCrossRef" href="#bib0270"><span class="elsevierStyleSup">15</span></a> adding clofazimine to the standard pattern of clarithromycin-ethambutol was associated with higher mortality rates, and did not improve the clinical response or microbiology.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The treatment of MAC-induced disseminated infections should be kept for at least 12 months, and it can be withdrawn in patients on antiretroviral therapy who reach virological suppression and CD4 counts over 100<span class="elsevierStyleHsp" style=""></span>cells/μl for more than 3–6<span class="elsevierStyleHsp" style=""></span>months.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Pulmonary infection due to <span class="elsevierStyleItalic">Mycobacterium avium</span> complex</span><p id="par0115" class="elsevierStylePara elsevierViewall">The early management of a MAC-induced pulmonary infection should include a combination of one macrolide, ethambutol, and one rifamycin.</p><p id="par0120" class="elsevierStylePara elsevierViewall">The clinical guidelines published by the ATS back in 2007<a class="elsevierStyleCrossRef" href="#bib0275"><span class="elsevierStyleSup">16</span></a> recommend the use of rifampicin preferably over rifabutin, while differentiating the courses of treatment based on whether we are treating fibrocavitary multibacillary or nodular-bronchiectasic types. For the management of the first ones, the recommendation includes using daily doses of oral drugs plus one aminoglycoside (amikacin or streptomycin), whereas for the management of nodular paucibacillary types, the recommendation includes using the drugs three (3) times a week while getting rid of the aminoglycoside. The duration of the treatment should be 18–24<span class="elsevierStyleHsp" style=""></span>months, for at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative. The microbiological cure occurs in no more than 50–60 per cent of the cases, with relapses with isolates showing macrolide-resistance that are often interpreted through molecular typing as re-infections due to new clones.<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">17</span></a></p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Lymphadenitis due to <span class="elsevierStyleItalic">Mycobacterium avium</span> complex</span><p id="par0125" class="elsevierStylePara elsevierViewall">NTM-induced cervical lymphadenitis in children occurs in kids between one (1) and four (4) years old and it is due to the MAC, and less frequently to <span class="elsevierStyleItalic">M. scrofulaceum</span> and <span class="elsevierStyleItalic">M. haemophilum</span>. It can resolve spontaneously or cause skin fistulae. The best results are obtained with surgical resection of the affected nodes, but it has not been established yet whether it is necessary to add pharmacological therapy with the usual patterns (macrolides, ethambutol, rifamycines).<a class="elsevierStyleCrossRef" href="#bib0260"><span class="elsevierStyleSup">13</span></a></p></span></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060"><span class="elsevierStyleItalic">Mycobacterium kansasii</span></span><p id="par0130" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">M. kansasii</span> is one photochromogenous mycobacterium that causes pulmonary infections with a fibrocavitary pattern similar to that of tuberculosis, and with less focal or disseminated infections in patients with HIV infections or with other causes of immunodeficiency.</p><p id="par0135" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">M. kansasii</span> is sensitive in vitro to rifamycins, isoniazid, macrolides, ethambutol, quinolones, streptomycin, linezolid, and cotrimoxazole. The in vitro activity of isoniazid against <span class="elsevierStyleItalic">M. kansasii</span> is lower than the vitro activity against <span class="elsevierStyleItalic">M. tuberculosis</span>, with MIC ranges between 0.5 and 5<span class="elsevierStyleHsp" style=""></span>μg/ml, that is, usually above the critical concentrations used against <span class="elsevierStyleItalic">M. tuberculosis</span> (0.2 and 1<span class="elsevierStyleHsp" style=""></span>μg/ml). Yet despite this fact, courses of treatment with rifampicin-isoniazid, and ethambutol are usually effective, being the primary rifampicin-resistance the reason that explains most therapeutic failures. As a matter of fact, it is recommended to conduct one rifampicin-sensitivity study in primary isolates of <span class="elsevierStyleItalic">M. kansasii</span> and extend the study of sensitivity to other drugs with MICs above 1<span class="elsevierStyleHsp" style=""></span>μg/ml.</p><p id="par0140" class="elsevierStylePara elsevierViewall">The most commonly used pattern is rifampicin-isoniazid-ethambutol for at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative. Optionally, one fourth drug may be used in the early stage of extensive disease, or until confirming sensitivity to rifampicin (streptomycin, clarithromycin, or quinolone). Some authors suggest substituting isoniazid for clarithromycin as the initial empirical pattern.<a class="elsevierStyleCrossRef" href="#bib0285"><span class="elsevierStyleSup">18</span></a></p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Other slowly growing mycobacteria</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070"><span class="elsevierStyleItalic">Mycobacterium xenopi</span></span><p id="par0145" class="elsevierStylePara elsevierViewall">Same as it happens with the MAC, <span class="elsevierStyleItalic">M. xenopi</span> is responsible for the fibrocavitary pulmonary or nodular disease and for the disseminated disease in immunodeficient patients.</p><p id="par0150" class="elsevierStylePara elsevierViewall">It can be contaminating—pseudoepidemias due to water contamination after bronchoscope cleaning procedures have been reported. Sensitivity studies are difficult to interpret due to its slow growth, although it is usually considered sensitive to rifampicin, ethambutol, clarithromycin and high concentrations of isoniazid. A combination of these drugs is recommended for 18–24<span class="elsevierStyleHsp" style=""></span>months, for at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative for pulmonary disease.<a class="elsevierStyleCrossRef" href="#bib0290"><span class="elsevierStyleSup">19</span></a></p></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075"><span class="elsevierStyleItalic">Mycobacterium malmoense</span></span><p id="par0155" class="elsevierStylePara elsevierViewall">It is responsible for pulmonary infections, lymphadenitis and tenosynovitis. It is treated with similar schemes than the ones used against the MAC, since with the difficulties and interpretation of in vitro sensitivity studies, it is considered sensitive to rifampicin, ethambutol, and clarithromycin.<a class="elsevierStyleCrossRef" href="#bib0295"><span class="elsevierStyleSup">20</span></a></p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080"><span class="elsevierStyleItalic">Mycobacterium szulgai</span></span><p id="par0160" class="elsevierStylePara elsevierViewall">It is responsible for pulmonary infections with fibrocavitary pattern, especially in patients with preexistent predisposing pulmonary conditions, and immunodeficient patients of disseminated and extrapulmonary infections.</p><p id="par0165" class="elsevierStylePara elsevierViewall">It is usually sensitive to rifampicin, isoniazid, ethambutol, quinolones, and macrolides. The treatment recommended includes, at least, three (3) active drugs for at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative for pulmonary disease.<a class="elsevierStyleCrossRef" href="#bib0300"><span class="elsevierStyleSup">21</span></a></p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085"><span class="elsevierStyleItalic">Mycobacterium ulcerans</span></span><p id="par0170" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">M. ulcerans</span> is responsible for Buruli ulcer—one very prevalent condition in the tropics of devastating consequences if misdiagnosed and not treated adequately. The primary culture of skin lesions is poorly sensitive; <span class="elsevierStyleItalic">M. ulcerans</span> grows slowly and needs additional media such as incubation at low temperatures (82.4–91.4<span class="elsevierStyleHsp" style=""></span>°F), and prolonged incubation. It is a condition basically managed surgically based on wide debridement and grafting. However, several studies suggest better results with an early course of pharmacological treatment with patterns including rifampicin, clarithromycin, and streptomycin.<a class="elsevierStyleCrossRef" href="#bib0305"><span class="elsevierStyleSup">22</span></a></p></span></span></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Rapidly growing mycobacteria</span><p id="par0175" class="elsevierStylePara elsevierViewall">Within the genus <span class="elsevierStyleItalic">Mycobacterium</span>, rapidly growing mycobacteria (RGM) represent, approximately, half of the species reported<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">23</span></a>; most of them are environmental mycobacteria that have never been confirmed to be disease-causing mycobacteria. However, some species have been said to be human pathogens, especially the group made up of different non-pigmented species (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). Aside from these species, there are other occasional cases of infections due to other rapidly growing mycobacteria,<a class="elsevierStyleCrossRefs" href="#bib0310"><span class="elsevierStyleSup">23,24</span></a> but most of these are exceptional cases.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Clinical manifestations</span><p id="par0180" class="elsevierStylePara elsevierViewall">The spectrum of infections due to RGM is wide and includes numerous clinical syndromes.<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">5,23,25,26</span></a> However, among them there are three (3) groups that are especially significant: respiratory infections, skin and soft tissue infections, and biomaterial-related infections. Each and every one of them with specific therapeutic issues.</p><p id="par0185" class="elsevierStylePara elsevierViewall">RGM-induced respiratory infections are usually chronic clinical manifestations associated with the presence of preexistent pulmonary conditions such as cystic fibrosis. These manifestations can affect preexistent pulmonary cavities such as bullae and scarring lesions of previous infections, especially tuberculosis, in which the mycobacterium will initially colonize the lesion and then proceed to invade the tissues, or appear as a bronchiectasis infection similar to the clinical manifestations due to slowly growing mycobacteria. One especially relevant aspect in this case is to identify the causing species, since the meaning of the isolates in the clinical samples is not the same in all species.<a class="elsevierStyleCrossRef" href="#bib0330"><span class="elsevierStyleSup">27</span></a> Also, as we will see below, the antimicrobial sensitivity is also variable, which is why this is a very important thing to take into consideration. In these clinical manifestations, the <span class="elsevierStyleItalic">M. abscessus</span> species is especially relevant since this mycobacterium leads to respiratory infections whose therapeutic complexity is such that these infections are very hard to cure. Also, the presence of clones of special pathogenicity capable of being transmitted across different countries has been reported,<a class="elsevierStyleCrossRef" href="#bib0335"><span class="elsevierStyleSup">28</span></a> meaning that it is very important to know different aspects such as epidemiology, underlying conditions, species and subspecies that cause the clinical manifestations, etc. before planning the optimal course of treatment.</p><p id="par0190" class="elsevierStylePara elsevierViewall">In the case of skin and soft tissue infections,<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">29</span></a> many of them are associated with cosmetic procedures such as mesotherapy, hair removal, or tattoos that cause chronic clinical manifestations which, although they are not life-threatening for the patient, do cause important esthetic complications even after these clinical manifestations have gone away.</p><p id="par0195" class="elsevierStylePara elsevierViewall">Biomaterial-related infections have been more and more relevant during the last few years, and these mycobacteria cause very different clinical manifestations within this group such as prosthetic osteojoint infections, intravascular catheter-related infections, prosthetic valve endocarditis, etc.<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">23</span></a> Today, all of these clinical presentations share one characteristic in common—the removal of the infected material as an indispensable condition to cure the patient, since the microbacterium usually found in this material creates some sort of biofilm on the surface of such material with the corresponding therapeutic difficulties that we will discuss below.</p></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Antimicrobial sensitivity</span><p id="par0200" class="elsevierStylePara elsevierViewall">One particular characteristic of RGM, especially the non-pigmentated strains, is its microbial sensitivity which is very different from that of slowly growing strains. Generally speaking, most non-pigmented RGM species are resistant to the usual anti-tuberculosis drugs such as isoniazid, rifampicin, ethambutol, pyrazinamide, and streptomycin, but they are sensitive to other antibiotics commonly used in the management of different bacterial infections such as macrolides, quinolones, cotrimoxazole, tetracyclines, aminoglycosides, linezolid, some beta-lactam antibiotics (cefoxitin, imipenem), or tigecycline.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">9,30</span></a> Recently, the standardization of the sensitivity studies for these organisms has been published as the SEIMC protocol published back in 2017 shows, where microdilution is established as the go-to technique for these sensitivity studies. One especially significant piece of information is that there can be a significant variation in the sensitivity patterns, not only among different species, but also among strains within the same species, which is why it is recommended to conduct individualized sensitivity studies in isolates considered relevant.</p><p id="par0205" class="elsevierStylePara elsevierViewall">In general, most strains and species are sensitive to amikacin and have low MICs to tigecycline, even though the specific cut-off point for this antibiotic has not been established yet. <span class="elsevierStyleItalic">M. abscessus</span> and <span class="elsevierStyleItalic">M. chelonae</span> are usually the most resistant species of all, which is why the most useful courses of treatment in these cases are macrolides (except for strains with an inducible type of methylase), cefoxitin, and aminoglycosides (especially tobramycin for the management of <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">chelonae</span>). The species of <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">fortuitum</span> complex are usually sensitive to quinolones, aminoglycosides, cotrimoxazole, and linezolid, but they can be resistant to macrolides in many cases. Other species such as <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">peregrinum</span>, <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mucogenicum</span>, or <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">mageritense</span> are usually sensitive to numerous antibiotics.<a class="elsevierStyleCrossRefs" href="#bib0220"><span class="elsevierStyleSup">5,9,23,30,31</span></a></p></span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Treatment recommendations</span><p id="par0210" class="elsevierStylePara elsevierViewall">The actual recommendations for the management of these infections are based on the clinical manifestations and type of isolated mycobacterium (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0215" class="elsevierStylePara elsevierViewall">Skin and soft tissue infections with poor clinical expression are usually paucibacillary, which means that they could be successfully treated with monotherapy using one active antimicrobial agent against the isolated strain. Usually, one macrolide (normally, clarithromycin) is used against the strains of the <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">abscessus-chelonae</span> in cases where the mycobacterium is sensitive and there is no inducible methylase, and one quinolone is used against the strains of the <span class="elsevierStyleItalic">M.<span class="elsevierStyleHsp" style=""></span>fortuitum complex</span>.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">9,23,29</span></a> As alternatives, cefoxitin, amikacin, cotrimoxazole, or tetracyclines can be used as long as the strain is sensitive in vitro. Although linezolid or tigecycline are usually active, there is not much clinical experience on this regard. One of the problems with these antibiotics is that they need a parenteral route of administration, with the corresponding longer hospital stays, since it is recommended that the duration of the treatment should not be shorter than 4–6 months; also, a second antibiotic can be administered during the first few weeks if the case is more severe.<a class="elsevierStyleCrossRefs" href="#bib0240"><span class="elsevierStyleSup">9,23,29</span></a></p><p id="par0220" class="elsevierStylePara elsevierViewall">If the bacillary load is significant (oversized abscesses, for example) we would need combination therapy in order to avoid the development of resistances following the chromosome mutation. These mutations have been reported in <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">chelonae</span>, and monotherapy with clarithromycin, in which one mutation in the 23S rDNA gene provides the strains with high level resistance against this antibiotic.<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">23</span></a> In these cases, the dose limitations are the same as in the former case, yet it has been reported that it is possible to use amikacin in alternative patterns of treatment (3–4<span class="elsevierStyleHsp" style=""></span>days a week) aimed at facilitating the extrahospitalary management of these patients. In these cases, it can be desirable and even necessary to proceed with the surgical drainage of the oversized abscesses in order to reduce the bacillary load.</p><p id="par0225" class="elsevierStylePara elsevierViewall">The management of RGM-induced respiratory infections is a real challenge these days. Most infections are due to <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">abscessus</span> (subespecies <span class="elsevierStyleItalic">abscessus</span> and <span class="elsevierStyleItalic">massiliense</span>), and in these cases there are not too many therapeutic options especially when it comes to administering oral treatment, above all, in cases due to strains with the functional <span class="elsevierStyleItalic">erm</span>(41) gene and, therefore, macrolide-resistant. In these cases, it is advisable to use 2–3 in vitro sensitive drugs, such as cefoxitin, amikacin, tigecycline, or imipenem, initially through parenteral rout of administration, and oral combination therapy with clarithromycin, if possible, if the isolate is sensitive to it, for at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative for respiratory samples. However, both the drug dose and toxicity limitations and the difficulty trying to eradicate the mycobacterium from the pulmonary tissue when it has created a biofilm makes the complete clinical-microbiological cure of these patients impossible,<a class="elsevierStyleCrossRef" href="#bib0355"><span class="elsevierStyleSup">32</span></a> which is why, in these cases, we will alleviate the symptom and limit the infection-induced pulmonary damage through successive cycles of treatment.<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">23</span></a> Nevertheless, in those cases where the strain is macrolide-sensitive, adding these drugs is a game changer in the prognosis of these patients, because it is feasible to cure them.<a class="elsevierStyleCrossRef" href="#bib0360"><span class="elsevierStyleSup">33</span></a> In the case of other species, the treatment will follow the same principles (use of 2–3<span class="elsevierStyleHsp" style=""></span>drugs the mycobacterium is sensitive to for at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative).</p><p id="par0230" class="elsevierStylePara elsevierViewall">When it comes to the management of biomaterial-related infections, it is essential to remove the infected material in order to cure these patients. In the case of intravascular catheter-related bacteremias,<a class="elsevierStyleCrossRef" href="#bib0365"><span class="elsevierStyleSup">34</span></a> or breast implant-related infections<a class="elsevierStyleCrossRef" href="#bib0310"><span class="elsevierStyleSup">23</span></a> it may not be that hard, but in other infections such as prosthetic joint infections,<a class="elsevierStyleCrossRef" href="#bib0370"><span class="elsevierStyleSup">35</span></a> or prosthetic valve endocarditis<a class="elsevierStyleCrossRef" href="#bib0325"><span class="elsevierStyleSup">26</span></a> it is much more complicated. In these cases, we should also use combination therapy based on the individualized study of the isolate-sensitivity in each case. Also, the course of treatment should last, at least 6<span class="elsevierStyleHsp" style=""></span>months, especially in the case of severe infections. We should also bear in mind that, yet despite the ominous prognosis of some of these infections, such as endocarditis, the cure has been reported in some cases, even without the removal of the prosthesis infected with <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">fortuitum</span>.<a class="elsevierStyleCrossRefs" href="#bib0375"><span class="elsevierStyleSup">36,37</span></a> The infection-causing species is probably something very important too when it comes to establishing the prognosis of the patient.</p></span></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110"><span class="elsevierStyleItalic">Mycobacterium marinum</span></span><p id="par0235" class="elsevierStylePara elsevierViewall">This mycobacterium has been described both as a rapidly and a slowly growing mycobacterium, since this characteristic depends on the temperature of incubation. The disease it causes is known as pool or fish tank granuloma, and it is usually described as one single granulomatous lesion that has an epidemiological precedent of contact with water from these places.<a class="elsevierStyleCrossRef" href="#bib0385"><span class="elsevierStyleSup">38</span></a></p><p id="par0240" class="elsevierStylePara elsevierViewall">In the case of <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">marinum</span> conducing systematic sensitivity tests is not advisable since, on many occasions, surgical excision of the lesion can be curative. However, it is usually sensitive to some conventional anti-tuberculosis drugs such as rifampicin or ethambutol (both used clinically with good results), and tetracyclines, cotrimoxazole, or clarithromycin.<a class="elsevierStyleCrossRefs" href="#bib0385"><span class="elsevierStyleSup">38,39</span></a> Generally, empirical treatment with ethambutol plus clarithromycin and, on some occasions, rifampicin is administered for at least 2 months from the moment of clinical recovery (total: 3–6<span class="elsevierStyleHsp" style=""></span>months). Monotherapy, especially quinolones, is not recommended since there is a risk of developing resistant mutants with the corresponding therapeutic failure.<a class="elsevierStyleCrossRef" href="#bib0340"><span class="elsevierStyleSup">29</span></a></p></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Conclusions</span><p id="par0245" class="elsevierStylePara elsevierViewall">There is a wide spectrum of infections due to nontuberculous mycobacteria, and the number of infections is growing since the number of susceptible patients is growing as well. Although the management of these infections has not been studied as much as <span class="elsevierStyleItalic">M.</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">tuberculosis</span>, there is enough evidence to study it based on the actual knowledge on the medical literature and the advances made in microbiological techniques. However, the basis for the management of these patients is the correct interpretation of the isolates in order to differentiate genuine infections from colonizations or contaminations. Once the diagnosis of infection has been achieved, the management of the patient should be adjusted to the location of both the infection and the causing mycobacterium. These can be very long courses of treatment and, in some cases, they can have poor outcomes because of the highly specific nature of these conditions. This is why it is essential that the management of these patients is conducted by expert multidisciplinary teams that are savvy on this type of infections so that the patients can have the best possible results.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Conflict of interests</span><p id="par0250" class="elsevierStylePara elsevierViewall">There are no conflicts of interest related to this manuscript whatsoever.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1100403" "titulo" => "Abstract" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0005" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1041464" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1100402" "titulo" => "Resumen" "secciones" => array:1 [ 0 => array:1 [ "identificador" => "abst0010" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1041463" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Biofilms and therapeutic complications" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Slowly growing mycobacteria" "secciones" => array:3 [ 0 => array:3 [ "identificador" => "sec0020" "titulo" => "Mycobacterium avium complex" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0025" "titulo" => "Disseminated infection in HIV-positive patients" ] 1 => array:2 [ "identificador" => "sec0030" "titulo" => "Pulmonary infection due to Mycobacterium avium complex" ] 2 => array:2 [ "identificador" => "sec0035" "titulo" => "Lymphadenitis due to Mycobacterium avium complex" ] ] ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Mycobacterium kansasii" ] 2 => array:3 [ "identificador" => "sec0045" "titulo" => "Other slowly growing mycobacteria" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Mycobacterium xenopi" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Mycobacterium malmoense" ] 2 => array:2 [ "identificador" => "sec0060" "titulo" => "Mycobacterium szulgai" ] 3 => array:2 [ "identificador" => "sec0065" "titulo" => "Mycobacterium ulcerans" ] ] ] ] ] 7 => array:3 [ "identificador" => "sec0070" "titulo" => "Rapidly growing mycobacteria" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0075" "titulo" => "Clinical manifestations" ] 1 => array:2 [ "identificador" => "sec0080" "titulo" => "Antimicrobial sensitivity" ] 2 => array:2 [ "identificador" => "sec0085" "titulo" => "Treatment recommendations" ] ] ] 8 => array:2 [ "identificador" => "sec0090" "titulo" => "Mycobacterium marinum" ] 9 => array:2 [ "identificador" => "sec0095" "titulo" => "Conclusions" ] 10 => array:2 [ "identificador" => "sec0100" "titulo" => "Conflict of interests" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-09-28" "fechaAceptado" => "2017-10-12" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1041464" "palabras" => array:3 [ 0 => "Nontuberculous mycobacteria" 1 => "Treatment" 2 => "Clinical significance" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1041463" "palabras" => array:3 [ 0 => "Micobacterias no tuberculosas" 1 => "Tratamiento" 2 => "Significado clínico" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:2 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Nontuberculous mycobacteria are a heterogeneous group of microorganisms that can often cause human infection, although they may also be considered to be contaminants or colonizers on occasions. The management of these infections must necessarily take into account the identification of isolated species and their in vitro susceptibility testing (although not for all of them), as well as the characteristics of the patient, because these treatments are usually prolonged and must be carried out by experts in the management of these infections. Classically divided into slowly growing mycobacteria and rapidly growing mycobacteria, the treatment regimens and the antibiotics used are different for both groups. In addition, in certain circumstances, this treatment must necessarily be linked to other measures (removal of foreign bodies, surgery) in order to maximize the likelihood of curing the patient.</p></span>" ] "es" => array:2 [ "titulo" => "Resumen" "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Las micobacterias no tuberculosas forman un grupo heterogéneo de microorganismos que en numerosas ocasiones son causa de infección en humanos, si bien también pueden considerarse en ocasiones como contaminantes o colonizadores. El manejo de estas infecciones debe necesariamente tener en cuenta la especie aislada y su sensibilidad in vitro (aunque no en todas ellas), así como las características del propio paciente, ya que estos tratamientos suelen ser prolongados y, necesariamente, deben ser llevados a cabo por expertos en el manejo de estas infecciones. Clásicamente divididas en micobacterias de crecimiento lento y micobacterias de crecimiento rápido, los esquemas de tratamiento y los antibióticos empleados son diferentes en ambos casos. Además, en determinadas circunstancias este tratamiento deberá necesariamente ir unido a otras medidas (retirada de cuerpos extraños, cirugía) con el objetivo de tener las máximas posibilidades de conseguir la curación del paciente.</p></span>" ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Please cite this article as: Esteban J, Navas E. Tratamiento de las infecciones producidas por micobacterias no tuberculosas. Enferm Infecc Microbiol Clin. 2018;36:586–592.</p>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 631 "Ancho" => 1000 "Tamanyo" => 96669 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Cavitary disease due to <span class="elsevierStyleItalic">Mycobacterium avium</span> (CT scan).</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Fig. 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 676 "Ancho" => 1000 "Tamanyo" => 129486 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Nodulary disease due to <span class="elsevierStyleItalic">Mycobacterium avium</span> (CT scan).</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Non-pigmented mycobacteria \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Pigmented mycobacteria \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium abscessus</span><br><span class="elsevierStyleHsp" style=""></span>Subsp. <span class="elsevierStyleItalic">abscessus</span><br><span class="elsevierStyleHsp" style=""></span>Subsp. <span class="elsevierStyleItalic">massiliense</span><br><span class="elsevierStyleHsp" style=""></span>Subsp. <span class="elsevierStyleItalic">bolletii</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium bacteremicum</span><br><span class="elsevierStyleItalic">Mycobacterium celeriflavum</span><br><span class="elsevierStyleItalic">Mycobacterium cosmeticum</span><br><span class="elsevierStyleItalic">Mycobacterium iranicum</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium chelonae</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium neoaurum</span> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium fortuitum</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium marinum</span><a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium porcinum</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Mycobacterium fortuitum</span> group \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium boenickei</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium houstonense</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium peregrinum</span><br><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium senegalense</span><br><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium septicum</span><br><span class="elsevierStyleItalic">Mycobacterium immunogenum</span><br><span class="elsevierStyleItalic">Mycobacterium mageritense</span><br><span class="elsevierStyleItalic">Mycobacterium wolinskyi</span><br><span class="elsevierStyleItalic">Mycobacterium canariasense</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a><br><span class="elsevierStyleItalic">Mycobacterium mucogenicum</span> group<br><span class="elsevierStyleItalic">Mycobacterium franklinii</span><br><span class="elsevierStyleItalic">Mycobacterium smegmatis</span> group<br><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium smegmatis</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a><br><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Mycobacterium goodii</span><a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1882773.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Late pigmentation.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Sometimes referred to as slow growth.</p> <p class="elsevierStyleNotepara" id="npar0015">Modified by Wallace et al.<a class="elsevierStyleCrossRef" href="#bib0280"><span class="elsevierStyleSup">17</span></a></p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Species of rapidly growing mycobacteria important to human pathology.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Dose:</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Rifampicin 600<span class="elsevierStyleHsp" style=""></span>mg/day; Rifabutin 150–300<span class="elsevierStyleHsp" style=""></span>mg.</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Isoniazid 300–600<span class="elsevierStyleHsp" style=""></span>mg/day.</p><p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Ethambutol 15<span class="elsevierStyleHsp" style=""></span>mg/kg/day.</p><p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Clarithromycin 500<span class="elsevierStyleHsp" style=""></span>mg every 12<span class="elsevierStyleHsp" style=""></span>h; Azithromycin 250<span class="elsevierStyleHsp" style=""></span>mg/day or 500<span class="elsevierStyleHsp" style=""></span>mg/t.i.d.</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">Streptomycin-Amikacin 10–15<span class="elsevierStyleHsp" style=""></span>mg/kg/day, or t.i.d.</p><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Levofloxacin 500<span class="elsevierStyleHsp" style=""></span>mg/day, or moxifloxacin 400<span class="elsevierStyleHsp" style=""></span>mg/day.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Mycobacteria \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Treatment \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Comment \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleItalic">M. avium complex</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Pulmonary<br>nodular-bronchiectasic \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin/Rifabutin<br>Ethambutol<br>Clarithromycin/Azithromycin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18–24 months; 12 months ever since the culture results test negative<br>Possibility of dose three days a week \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Fibrocavitary pumonary \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin/rifabutin<br>Ethambutol<br>Clarithromycin/Azithromycin<br>(Streptomycin/Amikacin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18–24 months; 12 months ever since the culture results test negative<br>Daily dose<br>Optional aminoglycoside in severe-extensive disease \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Disseminated infection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Clarithromycin/Azithromycin<br>Ethambutol<br>(Streptomycin/Amikacin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">At least 12 months and up to 3 months with CD4 counts ><span class="elsevierStyleHsp" style=""></span>50/μl and undetectable viral load<br>Optional aminoglycoside in severe-extensive disease \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. kansasii</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin<br>Ethambutol<br>Clarithromycin/Azithromycin<br>(Levo/Moxifloxacin)<br>(Streptomycin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 months ever since the culture results test negative for pulmonary disease<br>Rule out rifampicin-resistance<br>Optional streptomycin<br>The macrolide may be substitude for one quinolone \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. xenopi</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin<br>Isoniazid<br>Ethambutol<br>Clarithromycin/Azithromycin<br>(Streptomycin/Amikacin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18–24 months. 12 months ever since the culture results test negative for pulmonary disease<br><br>Optional streptomycin/Amikacin depending on severity \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. szulgai</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin/rifabutin<br>Ethambutol<br>Clarithromycin/Azithromycin<br>(Levo/Moxifloxacin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">12 months ever since the culture results test negative for pulmonary disease \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. malmoense</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin<br>Isoniazid<br>Ethambutol<br>Clarithromycin/Azithromycin<br>(Levo/Moxifloxacin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">18–24 months; 12 months ever since the culture results test negative for pulmonary disease \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. marinum</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Clarithromycin/Azithromycin<br>Ethambutol<br>(Rifampicin) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">4–6 months (2 months after the skin lesions resolved) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. ulcerans</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin 6 months<br>Clarithromycin 6 months<br>Streptomycin 2 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Rifampicin-clarithromycin 6<span class="elsevierStyleHsp" style=""></span>months<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>streptomycin during the first 2 months<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>surgical resection \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. abscessus</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Cefoxitin or Imipenem<br>Amikacin<br>Clarithromycin (if it is S)<br>Tigecycline/Doxycycline \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It should be adjusted individually for every strain and based on the antibiogram<br>In pulmonary infections: at least 12<span class="elsevierStyleHsp" style=""></span>months ever since the culture results test negative \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. chelonae</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Clarithromycin 6 months<br>Amikacin 6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It should be adjusted individually for every strain and based on the antibiogram \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">M. fortuitum</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Quinolone (Ciprofloxacin, Moxifloxacin) 6 months<br>Amikacin 6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It should be adjusted individually for every strain and based on the antibiogram \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Other rapidly growing mycobacteria</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Use 2 sensitive antibiotics in vitro \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">It should be adjusted individually for every strain and based on the antibiogram \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1882772.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Early management of nontuberculous mycobacteria (individualize if the treatment fails, when in re-treatment, and drug-resistance).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:39 [ 0 => array:3 [ "identificador" => "bib0200" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The new mycobacteria: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "E. Tortoli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1574-695X.2006.00123.x" "Revista" => array:6 [ "tituloSerie" => "FEMS Immunol Med Microbiol" "fecha" => "2006" "volumen" => "48" "paginaInicial" => "159" "paginaFinal" => "178" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17064273" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0205" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Microbiological features and clinical relevance of new species of the genus <span class="elsevierStyleItalic">Mycobacterium</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "E. Tortoli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CMR.00035-14" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Rev" "fecha" => "2014" "volumen" => "27" "paginaInicial" => "727" "paginaFinal" => "752" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25278573" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0210" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "“Why me, why now?” Using clinical immunology and epidemiology to explain who gets nontuberculous mycobacterial infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.A. Lake" 1 => "L.R. Ambrose" 2 => "M.C. Lipman" 3 => "D.M. Lowe" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/s12916-016-0606-6" "Revista" => array:5 [ "tituloSerie" => "BMC Med" "fecha" => "2016" "volumen" => "14" "paginaInicial" => "54" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27007918" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0215" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Host susceptibility to non-tuberculous mycobacterial infections" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "U.I. Wu" 1 => "S.M. Holland" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(15)00089-4" "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2015" "volumen" => "15" "paginaInicial" => "968" "paginaFinal" => "980" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26049967" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0220" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "B.A. Brown-Elliott" 1 => "K.A. Nash" 2 => "R.J. Wallace Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/CMR.05030-11" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Rev" "fecha" => "2012" "volumen" => "25" "paginaInicial" => "545" "paginaFinal" => "582" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22763637" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0225" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">Mycobacterium avium</span> biofilm attenuates mononuclear phagocyte function by triggering hyperstimulation and apoptosis during early infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "S.J. Rose" 1 => "L.E. Bermudez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/IAI.00820-13" "Revista" => array:6 [ "tituloSerie" => "Infect Immun" "fecha" => "2014" "volumen" => "82" "paginaInicial" => "405" "paginaFinal" => "412" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24191301" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0230" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biofilm development by clinical strains of non-pigmented rapidly growing mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N.Z. Martin-de-Hijas" 1 => "D. Garcia-Almeida" 2 => "G. Ayala" 3 => "R. Fernandez-Roblas" 4 => "I. Gadea" 5 => "A. Celdran" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1469-0691.2009.02882.x" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2009" "volumen" => "15" "paginaInicial" => "931" "paginaFinal" => "936" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19624503" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0235" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "In vitro susceptibility of rapidly growing mycobacteria biofilms against different antimicrobials" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "M.C. Munoz-Egea" 1 => "M. Garcia-Pedrazuela" 2 => "J. Esteban" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2014.04.010" "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2015" "volumen" => "33" "paginaInicial" => "136" "paginaFinal" => "137" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25027696" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0240" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current treatment of nontuberculous mycobacteriosis: an update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J. Esteban" 1 => "M. Garcia-Pedrazuela" 2 => "M.C. Munoz-Egea" 3 => "F. Alcaide" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14656566.2012.677824" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Pharmacother" "fecha" => "2012" "volumen" => "13" "paginaInicial" => "967" "paginaFinal" => "986" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22519767" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0245" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Biofilm formation by <span class="elsevierStyleItalic">Mycobacterium abscessus</span> in a lung cavity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.P. Fennelly" 1 => "C. Ojano-Dirain" 2 => "Q. Yang" 3 => "L. Liu" 4 => "L. Lu" 5 => "A. Progulske-Fox" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201508-1586IM" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2016" "volumen" => "193" "paginaInicial" => "692" "paginaFinal" => "693" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26731090" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0250" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of antibiotics and antibiofilm agents in the ultrastructure and development of biofilms developed by nonpigmented rapidly growing mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.C. Munoz-Egea" 1 => "M. Garcia-Pedrazuela" 2 => "I. Mahillo-Fernandez" 3 => "J. Esteban" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1089/mdr.2015.0124" "Revista" => array:6 [ "tituloSerie" => "Microb Drug Resist" "fecha" => "2016" "volumen" => "22" "paginaInicial" => "1" "paginaFinal" => "6" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26208145" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0255" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Comparison of clinical features, virulence, and relapse among <span class="elsevierStyleItalic">Mycobacterium avium</span> complex species" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "D.P. Boyle" 1 => "T.R. Zembower" 2 => "S. Reddy" 3 => "C. Qi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201501-0067OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2015" "volumen" => "191" "paginaInicial" => "1310" "paginaFinal" => "1317" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25835090" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0260" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The management of non-tuberculous cervicofacial lymphadenitis in children: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "P. Zimmermann" 1 => "M. Tebruegge" 2 => "N. Curtis" 3 => "N. Ritz" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jinf.2015.02.010" "Revista" => array:6 [ "tituloSerie" => "J Infect" "fecha" => "2015" "volumen" => "71" "paginaInicial" => "9" "paginaFinal" => "18" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25727993" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0265" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Macrolide/Azalide therapy for nodular/bronchiectatic <span class="elsevierStyleItalic">Mycobacterium avium</span> complex lung disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.J. Wallace Jr." 1 => "B.A. Brown-Elliott" 2 => "S. McNulty" 3 => "J.V. Philley" 4 => "J. Killingley" 5 => "R.W. Wilson" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1378/chest.13-2538" "Revista" => array:6 [ "tituloSerie" => "Chest" "fecha" => "2014" "volumen" => "146" "paginaInicial" => "276" "paginaFinal" => "282" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24457542" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0270" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic <span class="elsevierStyleItalic">Mycobacterium avium</span> complex disease in patients with HIV infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.E. Chaisson" 1 => "P. Keiser" 2 => "M. Pierce" 3 => "W.J. Fessel" 4 => "J. Ruskin" 5 => "C. Lahart" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "AIDS" "fecha" => "1997" "volumen" => "11" "paginaInicial" => "311" "paginaFinal" => "317" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9147422" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0275" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.E. Griffith" 1 => "T. Aksamit" 2 => "B.A. Brown-Elliott" 3 => "A. Catanzaro" 4 => "C. Daley" 5 => "F. Gordin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.200604-571ST" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2007" "volumen" => "175" "paginaInicial" => "367" "paginaFinal" => "416" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17277290" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0280" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Repeat positive cultures in <span class="elsevierStyleItalic">Mycobacterium intracellulare</span> lung disease after macrolide therapy represent new infections in patients with nodular bronchiectasis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "R.J. Wallace Jr." 1 => "Y. Zhang" 2 => "B.A. Brown-Elliott" 3 => "M.A. Yakrus" 4 => "R.W. Wilson" 5 => "L. Mann" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/341207" "Revista" => array:6 [ "tituloSerie" => "J Infect Dis" "fecha" => "2002" "volumen" => "186" "paginaInicial" => "266" "paginaFinal" => "273" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/12134265" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0285" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical and radiological features of <span class="elsevierStyleItalic">Mycobacterium kansasii</span> infection and <span class="elsevierStyleItalic">Mycobacterium simiae</span> infection" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D. Shitrit" 1 => "N. Peled" 2 => "J. Bishara" 3 => "R. Priess" 4 => "S. Pitlik" 5 => "Z. Samra" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.rmed.2008.05.004" "Revista" => array:6 [ "tituloSerie" => "Respir Med" "fecha" => "2008" "volumen" => "102" "paginaInicial" => "1598" "paginaFinal" => "1603" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18619826" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0290" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of slowly growing mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.V. Philley" 1 => "D.E. Griffith" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ccm.2014.10.005" "Revista" => array:6 [ "tituloSerie" => "Clin Chest Med" "fecha" => "2015" "volumen" => "36" "paginaInicial" => "79" "paginaFinal" => "90" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25676521" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0295" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The rising incidence and clinical relevance of <span class="elsevierStyleItalic">Mycobacterium malmoense</span>: a review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Hoefsloot" 1 => "M.J. Boeree" 2 => "J. van Ingen" 3 => "S. Bendien" 4 => "C. Magis" 5 => "W. de Lange" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Int J Tuberc Lung Dis" "fecha" => "2008" "volumen" => "12" "paginaInicial" => "987" "paginaFinal" => "993" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18713494" "web" => "Medline" ] ] ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0300" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Pulmonary infection due to <span class="elsevierStyleItalic">Mycobacterium szulgai</span>, case report and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "E. Tortoli" 1 => "G. Besozzi" 2 => "C. Lacchini" 3 => "V. Penati" 4 => "M.T. Simonetti" 5 => "S. Emler" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Eur Respir J" "fecha" => "1998" "volumen" => "11" "paginaInicial" => "975" "paginaFinal" => "977" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9623706" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0305" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antimicrobial treatment for early, limited <span class="elsevierStyleItalic">Mycobacterium ulcerans</span> infection: a randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W.A. Nienhuis" 1 => "Y. Stienstra" 2 => "W.A. Thompson" 3 => "P.C. Awuah" 4 => "K.M. Abass" 5 => "W. Tuah" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(09)61962-0" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2010" "volumen" => "375" "paginaInicial" => "664" "paginaFinal" => "672" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20137805" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0310" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rapidly growing mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B.A. Brown-Elliott" 1 => "J.V. Philley" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/microbiolspec.TNMI7-0027-2016" "Revista" => array:3 [ "tituloSerie" => "Microbiol Spectr" "fecha" => "2017" "volumen" => "5" ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0315" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rapidly growing mycobacteria in human pathology" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "J. Esteban" 1 => "R. Fernandez Roblas" 2 => "F. Soriano" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2000" "volumen" => "18" "paginaInicial" => "279" "paginaFinal" => "286" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11075485" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0320" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The clinical presentation, diagnosis, and therapy of cutaneous and pulmonary infections due to the rapidly growing mycobacteria, <span class="elsevierStyleItalic">M. fortuitum</span> and <span class="elsevierStyleItalic">M. chelonae</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "R.J. Wallace Jr." ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Clin Chest Med" "fecha" => "1989" "volumen" => "10" "paginaInicial" => "419" "paginaFinal" => "429" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/2673650" "web" => "Medline" ] ] ] ] ] ] ] ] 25 => array:3 [ "identificador" => "bib0325" "etiqueta" => "26" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Spectrum of disease due to rapidly growing mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "R.J. Wallace Jr." 1 => "J.M. Swenson" 2 => "V.A. Silcox" 3 => "R.C. Good" 4 => "J.A. Tschen" 5 => "M.S. Stone" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Rev Infect Dis" "fecha" => "1983" "volumen" => "5" "paginaInicial" => "657" "paginaFinal" => "679" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/6353528" "web" => "Medline" ] ] ] ] ] ] ] ] 26 => array:3 [ "identificador" => "bib0330" "etiqueta" => "27" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Epidemiology of infections due to nonpigmented rapidly growing mycobacteria diagnosed in an urban area" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Madrid Study Group of Mycobacteria" "etal" => false "autores" => array:5 [ 0 => "J. Esteban" 1 => "N.Z. Martin-de-Hijas" 2 => "A.I. Fernandez" 3 => "R. Fernandez-Roblas" 4 => "I. Gadea" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10096-008-0521-7" "Revista" => array:6 [ "tituloSerie" => "Eur J Clin Microbiol Infect Dis" "fecha" => "2008" "volumen" => "27" "paginaInicial" => "951" "paginaFinal" => "957" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18458972" "web" => "Medline" ] ] ] ] ] ] ] ] 27 => array:3 [ "identificador" => "bib0335" "etiqueta" => "28" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.M. Bryant" 1 => "D.M. Grogono" 2 => "D. Rodriguez-Rincon" 3 => "I. Everall" 4 => "K.P. Brown" 5 => "P. Moreno" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1126/science.aaf8156" "Revista" => array:6 [ "tituloSerie" => "Science" "fecha" => "2016" "volumen" => "354" "paginaInicial" => "751" "paginaFinal" => "757" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27846606" "web" => "Medline" ] ] ] ] ] ] ] ] 28 => array:3 [ "identificador" => "bib0340" "etiqueta" => "29" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cutaneous and soft skin infections due to non-tuberculous mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "F. Alcaide" 1 => "J. Esteban" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0213-005X(10)70008-2" "Revista" => array:7 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2010" "volumen" => "28" "numero" => "Suppl. 1" "paginaInicial" => "46" "paginaFinal" => "50" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20172423" "web" => "Medline" ] ] ] ] ] ] ] ] 29 => array:3 [ "identificador" => "bib0345" "etiqueta" => "30" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Methods for determining the antimicrobial susceptibility of mycobacteria" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. Alcaide" 1 => "J. Esteban" 2 => "J. Gonzalez-Martin" 3 => "J.J. Palacios" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.eimc.2016.04.008" "Revista" => array:6 [ "tituloSerie" => "Enferm Infecc Microbiol Clin" "fecha" => "2017" "volumen" => "35" "paginaInicial" => "529" "paginaFinal" => "535" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27236235" "web" => "Medline" ] ] ] ] ] ] ] ] 30 => array:3 [ "identificador" => "bib0350" "etiqueta" => "31" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Current treatment of atypical mycobacteriosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J. Esteban" 1 => "A. Ortiz-Perez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1517/14656560903369363" "Revista" => array:6 [ "tituloSerie" => "Expert Opin Pharmacother" "fecha" => "2009" "volumen" => "10" "paginaInicial" => "2787" "paginaFinal" => "2799" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19929702" "web" => "Medline" ] ] ] ] ] ] ] ] 31 => array:3 [ "identificador" => "bib0355" "etiqueta" => "32" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics and treatment outcomes of patients with acquired macrolide-resistant <span class="elsevierStyleItalic">Mycobacterium abscessus</span> lung disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H. Choi" 1 => "S.Y. Kim" 2 => "D.H. Kim" 3 => "H.J. Huh" 4 => "C.S. Ki" 5 => "N.Y. Lee" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/AAC.01146-17" "Revista" => array:4 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2017" "volumen" => "61" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28264855" "web" => "Medline" ] ] ] ] ] ] ] ] 32 => array:3 [ "identificador" => "bib0360" "etiqueta" => "33" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Multidrug-resistant nontuberculous mycobacteria isolated from cystic fibrosis patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P.H. Candido" 1 => "S. Nunes Lde" 2 => "E.A. Marques" 3 => "T.W. Folescu" 4 => "F.S. Coelho" 5 => "V.C. De Moura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/JCM.00549-14" "Revista" => array:6 [ "tituloSerie" => "J Clin Microbiol" "fecha" => "2014" "volumen" => "52" "paginaInicial" => "2990" "paginaFinal" => "2997" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24920766" "web" => "Medline" ] ] ] ] ] ] ] ] 33 => array:3 [ "identificador" => "bib0365" "etiqueta" => "34" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rapidly growing mycobacterial bloodstream infections" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "G. El Helou" 1 => "G.M. Viola" 2 => "R. Hachem" 3 => "X.Y. Han" 4 => "I.I. Raad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S1473-3099(12)70316-X" "Revista" => array:6 [ "tituloSerie" => "Lancet Infect Dis" "fecha" => "2013" "volumen" => "13" "paginaInicial" => "166" "paginaFinal" => "174" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23347634" "web" => "Medline" ] ] ] ] ] ] ] ] 34 => array:3 [ "identificador" => "bib0370" "etiqueta" => "35" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prosthetic joint infection due to rapidly growing mycobacteria: report of 8 cases and review of the literature" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A.J. Eid" 1 => "E.F. Berbari" 2 => "I.G. Sia" 3 => "N.L. Wengenack" 4 => "D.R. Osmon" 5 => "R.R. Razonable" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/520982" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2007" "volumen" => "45" "paginaInicial" => "687" "paginaFinal" => "694" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/17712751" "web" => "Medline" ] ] ] ] ] ] ] ] 35 => array:3 [ "identificador" => "bib0375" "etiqueta" => "36" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prosthetic valve infective endocarditis with <span class="elsevierStyleItalic">Mycobacterium fortuitum</span>: antibiotics alone can be curative" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S.R. Gnanenthiran" 1 => "E.Y.T. Liu" 2 => "M. Wilson" 3 => "T. Chung" 4 => "T. Gottlieb" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.hlc.2017.05.135" "Revista" => array:6 [ "tituloSerie" => "Heart Lung Circ" "fecha" => "2017" "volumen" => "26" "paginaInicial" => "e86" "paginaFinal" => "e89" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28688832" "web" => "Medline" ] ] ] ] ] ] ] ] 36 => array:3 [ "identificador" => "bib0380" "etiqueta" => "37" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Successful treatment of <span class="elsevierStyleItalic">Mycobacterium fortuitum</span> prosthetic valve endocarditis: case report" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "G. Vail" 1 => "R. Kohler" 2 => "F. Steiner" 3 => "R. Donepudi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1086/313720" "Revista" => array:6 [ "tituloSerie" => "Clin Infect Dis" "fecha" => "2000" "volumen" => "30" "paginaInicial" => "629" "paginaFinal" => "630" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/10722472" "web" => "Medline" ] ] ] ] ] ] ] ] 37 => array:3 [ "identificador" => "bib0385" "etiqueta" => "38" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "<span class="elsevierStyleItalic">Mycobacterium marinum</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Aubry" 1 => "F. Mougari" 2 => "F. Reibel" 3 => "E. Cambau" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1128/microbiolspec.TNMI7-0038-2016" "Revista" => array:3 [ "tituloSerie" => "Microbiol Spectr" "fecha" => "2017" "volumen" => "5" ] ] ] ] ] ] 38 => array:3 [ "identificador" => "bib0390" "etiqueta" => "39" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antibiotic susceptibility pattern of <span class="elsevierStyleItalic">Mycobacterium marinum</span>" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Aubry" 1 => "V. Jarlier" 2 => "S. Escolano" 3 => "C. Truffot-Pernot" 4 => "E. Cambau" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Antimicrob Agents Chemother" "fecha" => "2000" "volumen" => "44" "paginaInicial" => "3133" "paginaFinal" => "3136" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11036036" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/2529993X/0000003600000009/v1_201810300607/S2529993X18300054/v1_201810300607/en/main.assets" "Apartado" => array:4 [ "identificador" => "71815" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Continuing medical education: Mycobacterial infections" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/2529993X/0000003600000009/v1_201810300607/S2529993X18300054/v1_201810300607/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2529993X18300054?idApp=UINPBA00004N" ]
Journal Information
Share
Download PDF
More article options
Continuing medical education: Mycobacterial infections
Treatment of infections caused by nontuberculous mycobacteria
Tratamiento de las infecciones producidas por micobacterias no tuberculosas